Merck slammed for 4,000% markup of taxpayer-funded Covid drug

The New Jersey-based pharmaceutical giant Merck is facing accusations of price gouging after it charged the U.S. over $700 per patient for a taxpayer-funded coronavirus treatment that, according to research, costs just $17.74 to produce. Last week, Merck announced plans to… Read more…

You may also like...